Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab
The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's sy...
Saved in:
| Published in | Internal Medicine Vol. 60; no. 4; pp. 639 - 643 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
The Japanese Society of Internal Medicine
15.02.2021
Japan Science and Technology Agency |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's syndrome developed a severe COVID-19 infection that required oxygen supplementation. After discussing the goals of care with him and his wife, off-label tocilizumab was given concomitantly, resulting in a rapid improvement in his symptoms and respiratory failure. This patient represents a supplementary case confirming the efficacy and safety of tocilizumab for COVID-19 in elderly patients with autoimmune diseases. |
|---|---|
| AbstractList | The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's syndrome developed a severe COVID-19 infection that required oxygen supplementation. After discussing the goals of care with him and his wife, off-label tocilizumab was given concomitantly, resulting in a rapid improvement in his symptoms and respiratory failure. This patient represents a supplementary case confirming the efficacy and safety of tocilizumab for COVID-19 in elderly patients with autoimmune diseases. The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's syndrome developed a severe COVID-19 infection that required oxygen supplementation. After discussing the goals of care with him and his wife, off-label tocilizumab was given concomitantly, resulting in a rapid improvement in his symptoms and respiratory failure. This patient represents a supplementary case confirming the efficacy and safety of tocilizumab for COVID-19 in elderly patients with autoimmune diseases.The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been reported as risk factors, but whether or not autoimmune diseases increase the risk remains unknown. An 85-year-old man with Sjögren's syndrome developed a severe COVID-19 infection that required oxygen supplementation. After discussing the goals of care with him and his wife, off-label tocilizumab was given concomitantly, resulting in a rapid improvement in his symptoms and respiratory failure. This patient represents a supplementary case confirming the efficacy and safety of tocilizumab for COVID-19 in elderly patients with autoimmune diseases. |
| Author | Kodama, Fumihiro Nagasaka, Atsushi Tomita, Tomoko Kataoka, Hiroshi Nishikawa, Shuji Kondo, Makoto Mukai, Masaya |
| Author_xml | – sequence: 1 fullname: Kataoka, Hiroshi organization: Department of Rheumatology and Clinical Immunology, Sapporo City General Hospital, Japan – sequence: 2 fullname: Kodama, Fumihiro organization: Department of Infectious Diseases, Sapporo City General Hospital, Japan – sequence: 3 fullname: Tomita, Tomoko organization: Department of Rheumatology and Clinical Immunology, Sapporo City General Hospital, Japan – sequence: 4 fullname: Kondo, Makoto organization: Department of Rheumatology and Clinical Immunology, Sapporo City General Hospital, Japan – sequence: 5 fullname: Nagasaka, Atsushi organization: Department of Infectious Diseases, Sapporo City General Hospital, Japan – sequence: 6 fullname: Nishikawa, Shuji organization: Department of Gastroenterology, Sapporo City General Hospital, Japan – sequence: 7 fullname: Mukai, Masaya organization: Department of Rheumatology and Clinical Immunology, Sapporo City General Hospital, Japan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33390490$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkkuOEzEQhi00iHnAFZAlFrDpwY92d3uDNEp4RBoRiQS2luOuThy57WB3BoVDcBwuwMXoJpkAEQs2VVb5r8-_VXWJznzwgBCm5JrRQr60voPotWuhtsZ6uC4IJRkjD9AF5bnMSsbFGbogklYZ68M5ukxpTQivSskeoXPOuSS5JBfo26QdILoDfNOCsyHqzgaPQ4NncAcR8AdIG9tXQ9zhsU1dhJSw9Xi2_vF9GcE_T3i283UMLeAvtlvh0fTTZJxRiecRem69r2o8s37pAI9DggE_bZrM6QU4PA_GOvt12-rFY_Sw0S7Bk0O-Qh_fvJ6P3mW307eT0c1tZkQluqypoajymhpa80YIRupGl3VOTWMgF4IwRnVdakl40aeq6I-iZLXkZiEWnDB-hV7tuZvtov-_Ad9F7dQm2lbHnQraqr9vvF2pZbhTpcwLQUUPeHEAxPB5C6lTrU0GnNMewjYplpeCSEEl76XPTqTrsB2mN6ikIJzQSvaqp386Olq5H9VvyyaGlCI0ytju17B6g9YpStSwG-p0N9SwG4oNgOoEcP_Gf7S-37euU6eXcGzUsbPGwb8aVT6EA-AoNCsdFXj-E3Lm5RY |
| CitedBy_id | crossref_primary_10_3389_fphar_2021_804250 crossref_primary_10_1002_iju5_12492 crossref_primary_10_3390_geriatrics7010022 crossref_primary_10_3390_jcm13103008 crossref_primary_10_23736_S2724_6329_23_04870_2 |
| Cites_doi | 10.1136/annrheumdis-2020-217424 10.1038/s41591-018-0036-4 10.1016/S2665-9913(20)30173-9 10.1016/S0140-6736(20)30566-3 10.1183/16000617.0011-2016 10.1016/j.autrev.2020.102564 10.1172/JCI137244 10.1126/scitranslmed.aac5415 10.1016/j.immuni.2020.04.003 |
| ContentType | Journal Article |
| Copyright | 2021 by The Japanese Society of Internal Medicine Copyright Japan Science and Technology Agency 2021 Copyright © 2021 by The Japanese Society of Internal Medicine |
| Copyright_xml | – notice: 2021 by The Japanese Society of Internal Medicine – notice: Copyright Japan Science and Technology Agency 2021 – notice: Copyright © 2021 by The Japanese Society of Internal Medicine |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TK 7U9 H94 K9. 7X8 5PM |
| DOI | 10.2169/internalmedicine.6010-20 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Neurosciences Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Neurosciences Abstracts MEDLINE - Academic |
| DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1349-7235 |
| EndPage | 643 |
| ExternalDocumentID | PMC7946515 33390490 10_2169_internalmedicine_6010_20 article_internalmedicine_60_4_60_6010_20_article_char_en |
| Genre | Journal Article Case Reports Report Case Study |
| GroupedDBID | --- 29J 2WC 5GY 7.U AAPBV ACPRK ADBBV AENEX AFRAH ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CS3 DIK DU5 EBS EJD F5P HYE JSF JSH M48 M~E OK1 P2P RJT RNS RPM RZJ TR2 XSB AAYXX CITATION OVT PGMZT CGR CUY CVF ECM EIF NPM 7T5 7TK 7U9 H94 K9. 7X8 5PM |
| ID | FETCH-LOGICAL-c585t-fde684d1c1d3f5520dfa7d41cfce4550221ad7a9036d7a867a9572d93cb5b3023 |
| IEDL.DBID | M48 |
| ISSN | 0918-2918 1349-7235 |
| IngestDate | Thu Aug 21 13:57:01 EDT 2025 Fri Jul 11 04:44:14 EDT 2025 Mon Jun 30 07:49:15 EDT 2025 Thu Apr 03 07:05:02 EDT 2025 Tue Jul 01 01:40:18 EDT 2025 Thu Apr 24 22:52:58 EDT 2025 Wed Apr 05 07:43:37 EDT 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 4 |
| Keywords | COVID-19 acute respiratory distress syndrome tocilizumab cytokine storm Sjögren's syndrome |
| Language | English |
| License | The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c585t-fde684d1c1d3f5520dfa7d41cfce4550221ad7a9036d7a867a9572d93cb5b3023 |
| Notes | ObjectType-Case Study-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Report-1 ObjectType-Feature-4 content type line 23 ObjectType-Article-3 Correspondence to Dr. Hiroshi Kataoka, hiroshi.kataoka@doc.city.sapporo.jp |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2169/internalmedicine.6010-20 |
| PMID | 33390490 |
| PQID | 2495030189 |
| PQPubID | 2048449 |
| PageCount | 5 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7946515 proquest_miscellaneous_2475095193 proquest_journals_2495030189 pubmed_primary_33390490 crossref_citationtrail_10_2169_internalmedicine_6010_20 crossref_primary_10_2169_internalmedicine_6010_20 jstage_primary_article_internalmedicine_60_4_60_6010_20_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-02-15 |
| PublicationDateYYYYMMDD | 2021-02-15 |
| PublicationDate_xml | – month: 02 year: 2021 text: 2021-02-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan – name: Tokyo |
| PublicationTitle | Internal Medicine |
| PublicationTitleAlternate | Intern. Med. |
| PublicationYear | 2021 |
| Publisher | The Japanese Society of Internal Medicine Japan Science and Technology Agency |
| Publisher_xml | – name: The Japanese Society of Internal Medicine – name: Japan Science and Technology Agency |
| References | 11. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. Forthcoming. 25. Tongyoo S, Permpikul C, Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care 20: 329, 2016. 20. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7: 303ra139, 2015. 3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054-1062, 2020. 13. Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. Forthcoming. 31. Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. Forthcoming. 12. Song J, Li Y, Huang X, et al. Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2. J Med Virol. Forthcoming. 15. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130: 2620-2629, 2020. 24. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. Forthcoming. 22. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology 2020. 23. Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes. Chest. Forthcoming. 30. Antinori S, Bonazzetti C, Gubertini G, et al. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Autoimmun Rev 19: 102564, 2020. 14. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A Review. JAMA. Forthcoming. 4. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79: 667-668, 2020. 18. Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. Forthcoming. 27. Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med (Lausanne) 7: 170, 2020. 6. Quartuccio L, Valent F, Pasut E, Tascini C, De Vita S. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine. Forthcoming. 16. Woodcock T, Barker P, Daniel S, et al. Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK. Anaesthesia 75: 654-663, 2020. 29. Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev 19: 102568, 2020. 7. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. Forthcoming. 10. Treatment guideline for COVID-19. 4th ed. The Japanese Association for Infectious Diseases [Internet]. [updated 2002 May 28; cited 2020 Jul 10]. Available from: https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_drug_200605.pd (in Japanese). 26. Tasaka S, Tatsumi K. Assembly of Pulmonary Circulation, Lung Injury tJRS clinical practice of acute respiratory distress syndrome in Japan: a nationwide survey and scientific evidences. Respir Investig 55: 257-263, 2017. 17. Hirano T, Murakami M. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity 52: 731-733, 2020. 1. World Health Organization. Clinical management of COVID-19: interim guidance. 2020. 2. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Forthcoming. 9. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging 101: 263-268, 2020. 21. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24: 739-748, 2018. 8. Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S. Pulmonary manifestations of Sjögren's syndrome. Eur Respir Rev 25: 110-123, 2016. 5. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. Forthcoming. 28. Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med 76: 43-49, 2020. 19. Goto H, Makita S, Kato K, et al. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. Int J Clin Oncol. Forthcoming. 22 23 24 25 cr-split#-10.2 26 cr-split#-10.1 27 28 29 30 31 11 12 13 14 15 16 17 18 19 1 2 F Zhou (3) 2020; 395 4 5 6 7 8 9 20 21 |
| References_xml | – reference: 20. Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 7: 303ra139, 2015. – reference: 2. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. Forthcoming. – reference: 27. Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med (Lausanne) 7: 170, 2020. – reference: 21. Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 24: 739-748, 2018. – reference: 30. Antinori S, Bonazzetti C, Gubertini G, et al. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Autoimmun Rev 19: 102564, 2020. – reference: 23. Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes. Chest. Forthcoming. – reference: 31. Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. Forthcoming. – reference: 25. Tongyoo S, Permpikul C, Mongkolpun W, et al. Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care 20: 329, 2016. – reference: 7. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. Forthcoming. – reference: 9. Hani C, Trieu NH, Saab I, et al. COVID-19 pneumonia: a review of typical CT findings and differential diagnosis. Diagn Interv Imaging 101: 263-268, 2020. – reference: 15. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130: 2620-2629, 2020. – reference: 4. Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 79: 667-668, 2020. – reference: 5. Favalli EG, Ingegnoli F, Cimaz R, Caporali R. What is the true incidence of COVID-19 in patients with rheumatic diseases? Ann Rheum Dis. Forthcoming. – reference: 11. Henderson LA, Canna SW, Schulert GS, et al. On the alert for cytokine storm: immunopathology in COVID-19. Arthritis Rheumatol. Forthcoming. – reference: 13. Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. Forthcoming. – reference: 18. Zhang X, Tan Y, Ling Y, et al. Viral and host factors related to the clinical outcome of COVID-19. Nature. Forthcoming. – reference: 17. Hirano T, Murakami M. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity 52: 731-733, 2020. – reference: 26. Tasaka S, Tatsumi K. Assembly of Pulmonary Circulation, Lung Injury tJRS clinical practice of acute respiratory distress syndrome in Japan: a nationwide survey and scientific evidences. Respir Investig 55: 257-263, 2017. – reference: 28. Campochiaro C, Della-Torre E, Cavalli G, et al. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med 76: 43-49, 2020. – reference: 1. World Health Organization. Clinical management of COVID-19: interim guidance. 2020. – reference: 8. Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S. Pulmonary manifestations of Sjögren's syndrome. Eur Respir Rev 25: 110-123, 2016. – reference: 22. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet Rheumatology 2020. – reference: 24. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19 - preliminary report. N Engl J Med. Forthcoming. – reference: 14. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A Review. JAMA. Forthcoming. – reference: 29. Toniati P, Piva S, Cattalini M, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev 19: 102568, 2020. – reference: 3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395: 1054-1062, 2020. – reference: 6. Quartuccio L, Valent F, Pasut E, Tascini C, De Vita S. Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy. Joint Bone Spine. Forthcoming. – reference: 16. Woodcock T, Barker P, Daniel S, et al. Guidelines for the management of glucocorticoids during the peri-operative period for patients with adrenal insufficiency: guidelines from the Association of Anaesthetists, the Royal College of Physicians and the Society for Endocrinology UK. Anaesthesia 75: 654-663, 2020. – reference: 19. Goto H, Makita S, Kato K, et al. Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. Int J Clin Oncol. Forthcoming. – reference: 10. Treatment guideline for COVID-19. 4th ed. The Japanese Association for Infectious Diseases [Internet]. [updated 2002 May 28; cited 2020 Jul 10]. Available from: https://www.kansensho.or.jp/uploads/files/topics/2019ncov/covid19_drug_200605.pd (in Japanese). – reference: 12. Song J, Li Y, Huang X, et al. Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2. J Med Virol. Forthcoming. – ident: 2 – ident: 18 – ident: 12 – ident: 16 – ident: 14 – ident: 31 – ident: 28 – ident: 4 doi: 10.1136/annrheumdis-2020-217424 – ident: 24 – ident: 9 – ident: 7 – ident: 21 doi: 10.1038/s41591-018-0036-4 – ident: 26 – ident: #cr-split#-10.2 – ident: 22 doi: 10.1016/S2665-9913(20)30173-9 – ident: 5 – ident: 1 – volume: 395 start-page: 1054 issn: 0140-6736 year: 2020 ident: 3 publication-title: The Lancet doi: 10.1016/S0140-6736(20)30566-3 – ident: 8 doi: 10.1183/16000617.0011-2016 – ident: 11 – ident: 19 – ident: 13 – ident: 30 doi: 10.1016/j.autrev.2020.102564 – ident: 15 doi: 10.1172/JCI137244 – ident: 20 doi: 10.1126/scitranslmed.aac5415 – ident: 29 – ident: 17 doi: 10.1016/j.immuni.2020.04.003 – ident: 6 – ident: #cr-split#-10.1 – ident: 27 – ident: 25 – ident: 23 |
| SSID | ssj0038792 |
| Score | 2.302321 |
| Snippet | The coronavirus disease 2019 (COVID-19) pandemic has become an urgent global health issue. An older age and underlying conditions, such as diabetes, have been... |
| SourceID | pubmedcentral proquest pubmed crossref jstage |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 639 |
| SubjectTerms | acute respiratory distress syndrome Adrenal Cortex Hormones - therapeutic use Aged, 80 and over Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Autoimmune diseases Case Report Coronaviruses COVID-19 COVID-19 - complications COVID-19 - immunology Cytokine Release Syndrome cytokine storm Diabetes mellitus Drug Therapy, Combination Dyspnea - etiology Humans Internal medicine Male Off-Label Use Pandemics Public health Respiratory Distress Syndrome - drug therapy Respiratory Distress Syndrome - etiology Respiratory Insufficiency - drug therapy Risk factors SARS-CoV-2 Sjogren's syndrome Sjogren's Syndrome - complications Sjögren's syndrome Supplements tocilizumab |
| Title | Immediate Amelioration of Severe Respiratory Distress in Sjögren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab |
| URI | https://www.jstage.jst.go.jp/article/internalmedicine/60/4/60_6010-20/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/33390490 https://www.proquest.com/docview/2495030189 https://www.proquest.com/docview/2475095193 https://pubmed.ncbi.nlm.nih.gov/PMC7946515 |
| Volume | 60 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Internal Medicine, 2021/02/15, Vol.60(4), pp.639-643 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtNAEF6VgqpeEP81lGqRkDi5xLvrvwNCVUNpQKESSVBv1np_qCvHgSaRgIfo4_QFeDFm7LUhVUBcbMvesa2dbzwznp0ZQp4noeEK1Ixfh3ZFopkvZSx9qSxTTFhr65Ysww_R8US8Ow1PN0ibrugmcL7WtcN-UpOLcv_b1--vQeBf4TLmIEpfFs2_s7KNRu-jkwHsv0Fugn6KUVyHoost8CRO3Zqef1Jvky3OeYqRsRWddesczLbPZp1Fen1h5R-a6ugOue1MTHrQYOIu2TDVPbI1dA--Ty4H0zpfZGHowdSUhQMBnVk6MoBsQz_-jr_TftGkk9CioqPzn1fgn1cv5nTkKh1Q_JFLD08-Dfp-kNIx2qBGN2clHYFiLA3tz-YGb39irQ-oMyUdAybK4sdyKvMHZHL0Znx47Lu2DL4C32LhW22iROhABZrbMGQ9bWWsRaCsMpgjzVggdSxT0I2wSyI4DGOmU67yMMceRQ_JZjWrzA6hPFaYJpQzyYXgPSvzPAq1sBLsRmGZ8EjcTnymXM1ybJ1RZuC7IPey69zLkHsZ63kk6Ci_NHU7_oPmbcPbjsJJ7zqKTODGUXYDMVUOvjce2W3BkbWQzrDLNzqgSeqRZ91lkGYM0cjKzJY4Bi04tKo98qjBUvcyLRphUlZQ1g3ASuGrV6rirK4Yjl0EwHB9_Nd7PiHbDBfrYKebcJdsLi6W5ilYW4t8D_yMwfu9WoR-ARjMMfA |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Immediate+Amelioration+of+Severe+Respiratory+Distress+in+Sj%C3%B6gren%27s+Syndrome+with+COVID-19+Treated+with+a+Single+Dose+of+Off-label+Tocilizumab&rft.jtitle=Internal+medicine+%28Tokyo%2C+1992%29&rft.au=Kataoka%2C+Hiroshi&rft.au=Kodama%2C+Fumihiro&rft.au=Tomita%2C+Tomoko&rft.au=Kondo%2C+Makoto&rft.date=2021-02-15&rft.eissn=1349-7235&rft.volume=60&rft.issue=4&rft.spage=639&rft_id=info:doi/10.2169%2Finternalmedicine.6010-20&rft_id=info%3Apmid%2F33390490&rft.externalDocID=33390490 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-2918&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-2918&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-2918&client=summon |